CBD

JULY 27, 2023 — CRN today provided written testimony to the U.S. House of Representatives Committee on Oversight and Accountability, Subcommittee on Health Care and Financial Services, asking that Congress demand FDA complete the work Congress directed the agency to do under the 2018 Farm Bill by permitting CBD and other hemp-derived cannabinoids to be lawfully marketed as dietary supplements using the appropriate safeguards found in the existing law.

CRN expressed dismay today about FDA’s denial of its 2020 citizen petition calling on the agency to create a regulatory pathway to legally market dietary supplements containing hemp-derived cannabidiol (CBD) and the agency’s separate announcement that FDA “has concluded a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks.”